SK pharmteco is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biopharmaceutical industries. With CGMP manufacturing sites, research and development facilities, and analytical laboratories across the United States, Europe, and South Korea, the company provides integrated services spanning Active Pharmaceutical Ingredients (APIs), advanced intermediates, registered starting materials, viral vectors for gene therapy, and analytical capabilities in support of client programs. SK pharmteco partners with companies of all sizes to enable the development and delivery of transformative therapies worldwide. The company is a subsidiary of SK Inc. (KRX: 034730), the strategic investment arm of SK Group, South Korea’s second-largest conglomerate.

Key Products and Services

• Small Molecule API Manufacturing: Expertise in producing complex APIs for various therapeutic areas.
• Cell and Gene Therapy Solutions: End-to-end support, including CGMP manufacturing, viral vector production, plasmid DNA manufacturing, and autologous/allogeneic cell therapy production.
• Process Development: Scalable, robust processes ensuring seamless tech transfer and compliance from preclinical to commercial stages.
• Analytical Services: Comprehensive testing for safety, potency, stability, and regulatory requirements.
• Regulatory Support: Guidance from clinical trials to regulatory submissions, ensuring global compliance.

SK Pharmteco’s innovative solutions and commitment to excellence have made them a partner of choice for life sciences companies worldwide. By combining cutting-edge technology with flexible, client-focused approaches, they play a pivotal role in advancing global healthcare solutions, delivering therapies that transform patients' lives